Evolving HCC Treatment: Combining Immunotherapy and TACE

Join us for an insightful discussion from ASCO 2026 as medical oncologists Dr. Antonella Cammarota and Professor Lorenza Rimassa delve into the latest advancements in hepatocellular carcinoma (HCC) management. In this episode, they explore the evolving multidisciplinary approach to HCC treatment, highlighting the importance of collaboration among medical oncologists, pathologists, interventional radiologists, and surgeons. Key topics include: • Recent phase III trial results combining immunotherapy with local regional therapies like TACE • The significance of integrating immunotherapy earlier in treatment and its implications for patient care • Patient selection criteria for the STRIDE regimen in the HIMALAYA trial and its long-term survival outcomes • The growing integration of local regional and systemic therapies, with a summary of various trials presented at ASCO Tune in to learn how these developments are shaping the future of HCC treatment and improving patient outcomes! Website: https://oncupdates.com/ Mail: [email protected] X/twitter: https://x.com/OncUpdates Don't forget to like, share, and subscribe for more updates from the world of oncology. #HepatocellularCarcinoma, #ASCO2026, #Immunotherapy, #TACE, #STRIDEregimen